Pham Hong Ngoc Thuy, Sakoff Jennette A, Bond Danielle R, Vuong Quan Van, Bowyer Michael C, Scarlett Christopher J
School of Environmental and Life Sciences, Faculty of Science, University of Newcastle, Brush Road, Ourimbah, NSW, 2258, Australia.
Faculty of Food Technology, Nha Trang University, No. 2 Nguyen Dinh Chieu Street, Nha Trang, Khanh Hoa, Vietnam.
Mol Biol Rep. 2018 Dec;45(6):2125-2133. doi: 10.1007/s11033-018-4370-x. Epub 2018 Sep 12.
Helicteres hirsuta Lour. (H. hirsuta) has been considered as a herbal medicine for the treatment of malaria and diabetes but limited studies have been conducted on its anticancer and antibacterial properties. In this study, the in vitro antibacterial and anticancer properties of the leaf and stem extracts and their two sub-fractions (aqueous and saponin-enriched butanol fractions) prepared from H. hirsuta were elucidated. MTT and CCK-8 assays were employed to assess their in vitro anticancer properties against various cancer cell lines. The antibacterial activity was assessed using the disc diffusion method and minimum inhibitory concentration (MIC) values were determined. The results revealed that the saponin-enriched fractions from H. hirsuta leaves and stems showed the highest antibacterial activity against E. coli (MIC values of 2.50 and 5.00 mg/mL, respectively) and S. lugdunensis (MIC values of 0.35 and 0.50 mg/mL, respectively). Importantly, these saponin-enriched fractions possessed strong anticancer activity in vitro towards a range of cancer cell lines including MIA PaCa-2 (pancreas); A2780 (ovarian); H460 (lung); A431 (skin); Du145 (prostate); HT29 (colon); MCF-7 (breast); SJ-G2, U87, SMA (glioblastoma) and BE2-C (neuroblastoma) at low doses (GI values of 0.36-11.17 µg/mL). They especially revealed potent anti-pancreatic cancer activity in vitro against MIA PaCa-2, BxPC-3 and CFPAC-1 cells with IC values of 1.80-6.43 µg/mL. This finding provides scientific evidence of the cytotoxic activity of the extracts prepared from H. hirsuta leaves and stems, and suggests further studies to isolate active compounds for development of new anticancer agents from these plant extracts.
粗毛山芝麻（Helicteres hirsuta Lour.，简称H. hirsuta）被视为一种用于治疗疟疾和糖尿病的草药，但对其抗癌和抗菌特性的研究有限。在本研究中，阐明了粗毛山芝麻叶和茎提取物及其两个亚组分（水相和富含皂苷的丁醇组分）的体外抗菌和抗癌特性。采用MTT和CCK-8测定法评估它们对各种癌细胞系的体外抗癌特性。使用纸片扩散法评估抗菌活性并确定最低抑菌浓度（MIC）值。结果显示，粗毛山芝麻叶和茎中富含皂苷的组分对大肠杆菌（MIC值分别为2.50和5.00 mg/mL）和路邓葡萄球菌（MIC值分别为0.35和0.50 mg/mL）表现出最高的抗菌活性。重要的是，这些富含皂苷的组分在体外对一系列癌细胞系具有强大的抗癌活性，包括MIA PaCa-2（胰腺）、A2780（卵巢）、H460（肺）、A431（皮肤）、Du145（前列腺）、HT29（结肠）、MCF-7（乳腺）、SJ-G2、U87、SMA（胶质母细胞瘤）和BE2-C（神经母细胞瘤），低剂量时（GI值为0.36 - 11.17 μg/mL）。它们尤其在体外对MIA PaCa-2、BxPC-3和CFPAC-1细胞显示出强大的抗胰腺癌活性，IC值为1.80 - 6.43 μg/mL。这一发现为粗毛山芝麻叶和茎提取物的细胞毒活性提供了科学证据，并建议进一步研究从这些植物提取物中分离活性化合物以开发新的抗癌药物。
